

RESEARCH NOTE

Open Access



Metronomic cyclophosphamide and metformin inhibited tumor growth and repopulated tumor-infiltrating lymphocytes in an experimental carcinoma model

Heba Mohamed Zaki¹, Khadiga Mohamed Ali², Mona Younis Youssef Abd Allah², Amoura Mohamed Abouelnaga¹, Mohamed Elsaid Abdraboh¹ and Osama Hussein^{3*}

Abstract

Metformin is a widely used antidiabetic biguanide. Retrospective data demonstrated the association of metformin use with survival benefit in multiple tumor types. Interest in repurposing metformin to treat cancer has not been translated into encouraging clinical benefit. In animal models, metformin activated cytotoxic T cells and exerted an immune-mediated anticancer effect. The current research was conducted to investigate the possible therapeutic benefit of metformin in combination with metronomic cyclophosphamide in an experimental cancer model. Ehrlich ascites carcinoma was injected into the subcutaneous tissue to induce solid tumors in syngeneic mice. Exponential solid tumor growth ensued and was effectively arrested with the administration of a cytotoxic dose of parenteral cyclophosphamide. Alternatively, oral metformin and continuous, low-dose cyclophosphamide significantly inhibited tumor growth relative to untreated mice. The drug combination was well tolerated. Histopathological examination of the tumor showed an increased number of tumor-infiltrating lymphocytes and enhanced expression of granzyme B by this drug combination. The current data suggests a potential role of metformin and metronomic chemotherapy that warrants further investigation.

Keywords Metformin, Metronomic therapy, Tumor infiltrating lymphocytes, Animal model

*Correspondence:

Osama Hussein
osamahussein@mans.edu.eg

¹Zoology Department, Faculty of Science, Mansoura University,
Mansoura 35516, Egypt

²Pathology Department, Faculty of Medicine, Mansoura University,
Mansoura 35516, Egypt

³Surgical Oncology Department, Faculty of Medicine, Mansoura
University Oncology Center, Mansoura University, Mansoura 35516, Egypt



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Interest in repurposing metformin to treat cancer has followed the impressive benefit observed in multiple epidemiological studies [1–8]. Several mechanistic theories explain the antitumor effect of metformin, including direct antiproliferative effects on cancer cells, direct and systemic metabolic actions, and immune-mediated mechanisms [9, 10]. Following the demonstration of the stimulatory effect of metformin on cytotoxic T cells in animal tumor models [11–13] and clinical studies [14], several experimental strategies were investigated with variable success, including combining metformin with radiotherapy [15], tumor vaccination [16], checkpoint blockade [17, 18], and cytotoxic chemotherapy [19].

Metronomic (continuous, low-dose) chemotherapy is a treatment modality that has a well-known immune-stimulatory effect in both experimental [20] and clinical [21, 22] settings.

This study was undertaken to explore the possibility of the therapeutic benefit of combined metformin and metronomic cyclophosphamide therapy.

Methods

Experimental model

Ehrlich ascites carcinoma (EAC) in female Swiss albino mice harboring 8–10-day-old ascitic tumors was purchased from the Egyptian National Cancer Institute, Cairo University. To induce solid tumor formation, EAC cells (2.5×10^6) were injected subcutaneously in the right flank of six- to eight-week-old female Swiss albino mice weighing 20–25 gm purchased from Vacsera Co., Egypt.

Mice that developed palpable tumors were randomly assigned to five groups of five mice each. Four treatment groups and one untreated control group. Treatment was either cytotoxic (bolus, high-dose) cyclophosphamide (Cyclo), metronomic (continuous, low-dose) cyclophosphamide, metformin, or combined metformin and metronomic cyclophosphamide.

Drugs

High-dose cyclophosphamide (Endoxan®, Baxter, CA®) was administered at a dose of 100–150 mg/kg by intraperitoneal injection every other day for 3 weeks followed by 2 weeks of rest.

Metronomic cyclophosphamide was described previously [23]. The drug was dissolved in distilled water (stock solution 20 mg/ml) and kept at 4 °C in the dark for one week. A total of 1.25 ml of stock solution was dissolved in 200 ml water at a concentration of 20 mg/kg dose.

The metformin “Glucophage®, Merck, NJ” dosage was 5 mg/ml dissolved in drinking water to provide a dose of 5 mg/kg. Drinking water was changed twice weekly.

Physical parameters

Tumor volume was measured at baseline and weekly thereafter for 4 weeks. The tumor volume of each animal was calculated using the ellipsoid formula: (Volume=length x width²×0.5). At the end of the fourth week, all mice were euthanized by thiopental overdose (150 mg/kg) intraperitoneal injection, followed by cervical dislocation, and the tumors were resected, measured, and preserved in formalin.

Histology and immunohistochemistry

Tumor-infiltrating lymphocytes (TILs) were assessed in H&E sections by counting all mononuclear cells in the peritumoral stroma. Tumor paraffin sections were deparaffinized and retrieved using 0.01 M citrate buffer (pH=6). After washing with PBS, the sections were quenched with 3% hydrogen peroxide, washed, blocked with horse normal serum, and then incubated with primary antibodies against Granzyme B (Cell Signaling Technology, MA; Catalog # 44153) and PD-1/CD279 (Chongqing Biospes, China; Catalog # YPA1638) at 4 °C overnight. IHC scoring was performed for granzyme B according to Kavalari et al. [24]. In brief, lymphocytes with a sparsely granulated pattern were counted in three fields (x400) at highly cellular areas of the tumor. Reactivity was graded as mild, moderate or marked if <5, 6–10 or ≥11 lymphocytes were present, respectively.

For PD-1 immune staining, the score used depended on combining the staining intensity with the percentage of immunoreactive cells. The staining intensity was scored from 0 (negative) to 3 (intense). The percentage of immunoreactive cells was scored as 1 (<5% positive cells) or 2 (≥5% positive cells). Then, the immunoreactive score (IRS) was calculated by multiplying the staining intensity score by the score of the percentage of immunoreactive cells. In all immunohistochemistry (IHC) experiments, a blinded pathologist examined two independent specimens per condition.

Statistical analysis

The results are presented as the median and interquartile range (IQR). The Mann–Whitney test was used to compare normalized tumor volumes. Grubb’s test was used to detect outliers. JASP 0.17.1.0 (© University of Amsterdam) and GraphPad™ Quick Calculator were used for calculations.

Results

Combined therapy inhibited tumor growth

Data from three independent experiments were pooled and normalized. The change in tumor volume relative to the baseline volume at the start of therapy was plotted over time. In total, 56 mice had measurable tumors in the fourth week. One mouse had an outlier measurement




Fig. 1 A) Change in tumor volume normalized to the original size at the start of treatment. B) volume at the third week in mice treated with combination of oral metformin and metronomic therapy compared to untreated tumors




Fig. 2 Kaplan-Meier's curve of three pooled experiments showing percent survival at weeks three and four

by Grubb's test (value=33.2, Z score=3.013, $P < 0.05$) and was excluded. Mice treated with high-dose Cyclo showed arrested tumor growth. However, survival was shortened in eight mice. Combined metronomic therapy and metformin, but not either drug alone, significantly inhibited tumor growth compared with the untreated group (Fig. 1a). Growth inhibition was significant at week 3 ($P = 0.021$, Mann-Whitney) and marginally significant at week 4 ($P = 0.064$) (Fig. 1b). At week 3, all mice treated with either metformin or low-dose cyclophosphamide

alone were alive. At this time point, 80% of mice treated with combination therapy, 60% of those treated with high-dose chemotherapy, and 67% of untreated mice were alive (Fig. 2).

Metformin repopulated tumor-infiltrating lymphocytes

Assessment of paraffin sections of untreated tumors showed inconsistent mild TIL infiltration. In this model, high-dose Cyclo abrogated the TIL population. Metformin and metronomic Cyclo alone or in combination consistently repopulated TILs (Table 1).

Combination therapy induced granzyme B expression

In general, the pattern of granzyme B expression followed the distribution of TILs in H&E sections. Consistent expression was observed in mice treated with combination therapy (Fig. 3).

The effect of combination therapy was not attributable to lymphocyte rejuvenation

Contrary to the hypothetical assumption, PD-1 expression was elevated with metformin, metronomic Cyclo or their combination (Table 1).

Discussion

In this study, an experimental murine cancer model was validated for therapeutic testing. High-dose Cyclo exerted constant arrest of otherwise exponential tumor growth. The therapeutic benefit of the metformin and

Table 1 Scoring of tumor-infiltrating lymphocytes (TILs). (Cyclo = cyclophosphamide, GZM B = granzyme B by immunohistochemistry). PD-1 score was calculated by multiplying the staining intensity score with the score of percentage of the immunoreactive cells

Specimen	TILs	GZM B	PD-1 score
Cyclo high	-	-	2
Cyclo high	-	-	
Cyclo + metformin	+	Mild	6
Cyclo + metformin	+	Mild	
Metformin	+	-	3
Metformin	+	Mild	
Cyclo low	-	-	4
Cyclo low	-	-	
Untreated	-	-	2
Untreated	+	Mild	




Fig. 3 Peritumoral (A, H&E, magnification x100) and intratumoral lymphocytic infiltrate (B, H&E, magnification x400). Immunohistochemistry for granzyme b showed positive cytoplasmic reaction in both peritumoral (C) and intratumoral (D) lymphocytic infiltrate (C & D, IHC, magnification x400)

metronomic Cyclo combination was demonstrated. Combination therapy but not monotherapy with either drug resulted in significant growth inhibition relative to untreated tumors. This growth inhibition came at the

expense of statistically insignificant decrease in mice survival with combination therapy. With high-dose chemotherapy, the loss of mice even exceeded that of the untreated group.

Drug treatment was associated with recovery of the TIL population, and granzyme B expression was maximal in mice that received the combination therapy. Although we hypothesized that combination treatment may help rejuvenate the TIL population, our data did not support this hypothesis. Combination therapy tripled the PD-1 exhaustion marker score over the untreated value. This finding suggests that the therapeutic benefit of the combination treatment is mediated through a mechanism that is either nonimmunological or independent of lymphocytic exhaustion. Alternatively, PD-1 ligand may be the primary target for metformin.

Although the antitumor benefit of metformin has been demonstrated in the clinical setting, the results of clinical trials have been largely disappointing thus far [10]. The immune-potentiating benefit of metformin is well described. Several authors have demonstrated the immunostimulatory mechanism of either metformin [9–14] or metronomic cyclophosphamide [20] alone. To our knowledge, the combination regimen has not been investigated to date.

Preclinical models may provide insight into the potential applicability of drug regimens and protocols and hopefully avoid the negative outcomes of labor- and cost-intensive clinical trials.

Limitations

In the current study, the findings in the experimental tumor model were not confirmed in models of murine orthotopic solid tumors. Lymphocyte characterization was performed with morphology alone, not with specific markers. A larger number of specimens is required to confirm the scoring results. Mechanistic studies are not covered in this research.

Abbreviations

Cyclo	Cyclophosphamide
EAC	Ehrlich ascites carcinoma
H&E	Hematoxylin and Eosin
PD-1	Programmed cell Death protein – 1
TILs	Tumor-Infiltrating Lymphocytes

Acknowledgements

The authors are indebted to their colleagues at the Department of Zoology at the Faculty of Science and at the Medical Experimental Research Center (MERC) and the Cord Blood Stem Cell Research Center at the Faculty of Medicine, Mansoura University.

Authors' contributions

H.M.Z. performed the animal experiments and drafted the manuscript, K.M.A. and M.Y.Y.A. performed the histopathology, A.M.A. and M.E.A. planned and supervised the experiments, O.H. conceived the study, planned and supervised the experiments and secured the funding. All authors shared designing, analyzing, and interpreting the results of some or all the experiments, and approved the manuscript.

Funding

This study was funded in part by an operating grant from Mansoura University to O.H. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Data availability

Not applicable.

Declarations

Ethics approval and consent to participate

All animal procedures were approved by the Ethics Committee of Mansoura University Faculty of Medicine (Code number: RP/17.10.113., Date: 28/10/2017). All procedures were performed in accordance with the Mansoura University Ethics Code and the regulations of the Ethics Committee of Mansoura University Faculty of Medicine.

Consent for publication

Not applicable.

Competing interests

All authors declare they have no competing interests relevant to this study.

Received: 9 April 2023 / Accepted: 4 December 2023

Published online: 02 January 2024

References

1. Scarton L, Jo A, Xie Z, O'Neal LJ, Munoz Pena JM, George TJ, et al. Examining the relationship between metformin dose and cancer survival: a SEER-Medicare analysis. *PLoS ONE*. 2022;17(10):e0275681.
2. Ng CW, Jiang AA, Toh EMS, Ng CH, Ong ZH, Peng S, et al. Metformin and Colorectal cancer: a systematic review, meta-analysis and meta-regression. *Int J Colorectal Dis*. 2020;35(8):1501–12.
3. Wan G, Sun X, Li F, Wang X, Li C, Li H, et al. Survival Benefit of Metformin Adjuvant Treatment for Pancreatic Cancer patients: a systematic review and Meta-analysis. *Cell Physiol Biochem*. 2018;49(3):837–47.
4. Zhou PT, Li B, Liu FR, Zhang MC, Wang Q, Li YY, et al. Metformin is associated with survival benefit in Pancreatic cancer patients with Diabetes: a systematic review and meta-analysis. *Oncotarget*. 2017;8(15):25242–50.
5. Zhong S, Wu Y, Yan X, Tang J, Zhao J. Metformin use and survival of Lung cancer patients: Meta-analysis findings. *Indian J Cancer*. 2017;54(1):63–7.
6. Li Y, Hu L, Xia Q, Yuan Y, Mi Y. The impact of metformin use on survival in kidney cancer patients with Diabetes: a meta-analysis. *Int Urol Nephrol*. 2017;49(6):975–81.
7. Ma SJ, Zheng YX, Zhou PC, Xiao YN, Tan HZ. Metformin use improves survival of diabetic Liver cancer patients: systematic review and meta-analysis. *Oncotarget*. 2016;7(40):66202–11.
8. Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 Diabetes: a systematic review and meta-analysis. *Oncologist*. 2013;18(12):1248–55.
9. Zhu H, Jia Z, Li YR, Danelisen I. Molecular mechanisms of action of metformin: latest advances and therapeutic implications. *Clin Exp Med*. 2023;1–11.
10. Lord SR, Harris AL. Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? *Br J Cancer*. 2023;128(6):958–66.
11. Wabitsch S, McCallen JD, Kamenyeva O, Ruf B, McVey JC, Kabat J, et al. Metformin treatment rescues CD8(+) T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. *J Hepatol*. 2022;77(3):748–60.
12. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, et al. Metformin promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated degradation of PD-L1. *Mol Cell*. 2018;71(4):606–20e7.
13. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 Diabetes drug, metformin. *Proc Natl Acad Sci U S A*. 2015;112(6):1809–14.
14. Tsukioki T, Shien T, Tanaka T, Suzuki Y, Kajihara Y, Hatono M, et al. Influences of preoperative metformin on immunological factors in early Breast cancer. *Cancer Chemother Pharmacol*. 2020;86(1):55–63.
15. Tojo M, Miyato H, Koinuma K, Horie H, Tsukui H, Kimura Y, et al. Metformin combined with local irradiation provokes abscopal effects in a murine rectal cancer model. *Sci Rep*. 2022;12(1):7290.

16. Munoz LE, Huang L, Bommireddy R, Sharma R, Monterroza L, Guin RN et al. Metformin reduces PD-L1 on Tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy. *J Immunother Cancer*. 2021;9(11).
17. Wei Z, Zhang X, Yong T, Bie N, Zhan G, Li X, et al. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. *Nat Commun*. 2021;12(1):440.
18. Chen S, Zhou X, Yang X, Li W, Li S, Hu Z et al. Dual blockade of Lactate/GPR81 and PD-1/PD-L1 pathways enhances the Anti-tumor effects of Metformin. *Biomolecules*. 2021;11(9).
19. Yang T, Yu S, Liu L, Sun Y, Lan Y, Ma X, et al. Dual polymeric prodrug co-assembled nanoparticles with precise ratiometric co-delivery of cisplatin and metformin for Lung cancer chemoimmunotherapy. *Biomater Sci*. 2020;8(20):5698–714.
20. Khan KA, Ponce de León JL, Benguigui M, Xu P, Chow A, Cruz-Muñoz W, et al. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine Breast cancer. *NPJ Breast Cancer*. 2020;6:29.
21. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, et al. Metronomic cyclophosphamide treatment in metastasized Breast cancer patients: immunological effects and clinical outcome. *Cancer Immunol Immunother*. 2012;61(3):353–62.
22. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients. *Cancer Immunol Immunother*. 2007;56(5):641–8.
23. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. *Cancer Res*. 2002;62(10):2731–5.
24. Kavalari R, Sarcevic B, Spagnoli GC, Separovic V, Samija M, Terracciano L, et al. Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study. *Virchows Arch*. 2001;439(2):127–31.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.